AbbVie Beats Q1 Estimates, Raises 2026 EPS Guidance
AbbVie (ABBV) reported quarterly earnings that beat analyst estimates and raised its adjusted earnings per share guidance for 2026. The stock rose 2.5% in premarket trading.
Key Numbers
AbbVie (ABBV) reported first-quarter 2026 financial results that exceeded analyst expectations, driven by strong performance of key drugs. The company raised its adjusted earnings per share guidance for the full year 2026, sending shares up 2.5% in premarket trading to $202.63.
Key Financial Results
| Metric | Value |
|---|---|
| Adjusted EPS Guidance (New) | $14.08 - $14.28 |
| Adjusted EPS Guidance (Old) | $13.96 - $14.16 |
| Stock Price (Premarket) | $202.63 |
Highlights from the Report
AbbVie reported better-than-expected quarterly earnings, though specific revenue or net income figures were not disclosed in the available report. The company focused on improving its annual guidance.
Future Guidance
AbbVie raised its 2026 adjusted earnings per share guidance to a range of $14.08 to $14.28, compared to the previous range of $13.96 to $14.16. This improvement reflects management's confidence in the company's performance.
Impact on the Stock
AbbVie shares rose 2.5% in premarket trading to $202.63, indicating a positive investor reaction to the results and improved guidance.
What This Means for Investors
AbbVie's results and improved guidance are a positive signal of the company's underlying business strength. However, investors should monitor the performance of key drugs and regulatory developments in the healthcare sector.
Frequently Asked Questions
Found this useful? Share it